Key Takeaways
- Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and a structural relationship to tuftsin.
- Published Selank research spans receptor-binding assays, cultured cells, rat brain tissue, animal behaviour models, and a limited number of human studies.
- Several studies implicate GABAergic signalling, but the results describe proposed molecular and network effects—not a settled clinical mechanism.
- A 2020 resting-state fMRI study included 52 healthy participants; older comparative clinical reports were small and geographically concentrated.
- Selank and Semax are distinct peptides with different parent sequences and different research emphases.
- The current evidence base is dominated by preclinical work and does not support human-use instructions or efficacy promises.
Selank research examines a tuftsin-derived heptapeptide in molecular, cellular, animal, and limited human models of GABAergic signalling, stress, behaviour, and brain connectivity. The strongest defensible conclusion is not that Selank has a proven therapeutic effect, but that it has a biologically active research profile supported by several independent experimental approaches. How those findings translate across species, laboratories, endpoints, or clinical settings remains uncertain.
Research boundary: This article is for research education only. BioPharma compounds are for laboratory and research use only, not for human or veterinary use. This is not medical advice and includes no dosing, route, administration, treatment, efficacy, or safety guidance.
What Is Selank?
Selank is the synthetic peptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. A 2018 molecular paper identifies it as a heptapeptide and evaluates its interaction with GABA-related binding systems. Reviews also describe it as an analogue of tuftsin, the tetrapeptide Thr-Lys-Pro-Arg, extended by Pro-Gly-Pro.
That structural description is more useful than broad labels such as “nootropic” or “anxiolytic,” because those labels can imply an outcome before the evidence has been examined. In a research brief, Selank is best treated as a defined peptide sequence with a heterogeneous literature base. Researchers should separate biochemical observations from cell-culture results, animal behaviour, brain-imaging measures, and patient-reported outcomes.
Why is it sometimes called TP-7?
TP-7 is shorthand for a seven-residue peptide, but it is not a reliable database identifier by itself. A same-day PubMed quality check showed that a combined “Selank OR TP-7” search retrieved many unrelated environmental, plant, and medical papers. This guide therefore cites only records whose titles and abstracts actually concern Selank.
How Does Selank Relate to Tuftsin?
Tuftsin is Thr-Lys-Pro-Arg. Selank retains that four-residue sequence and adds Pro-Gly-Pro. A 2017 review of tuftsin and its analogues catalogued the broader family and its varied experimental properties. Structural relatedness, however, does not mean that every reported tuftsin effect can be transferred to Selank. Each claim still requires Selank-specific evidence.
Why sequence identity matters in research
Exact identity matters for literature retrieval, analytical verification, and reproducibility. Similar names can refer to different sequences, and the same shorthand can retrieve unrelated records. Researchers evaluating a material should pair the label with sequence information and lot-specific analytical documentation. BioPharma’s certificate-of-analysis guide explains how to distinguish an identity claim from supporting analytical evidence.
What Mechanisms Does Selank Research Propose?
GABA-related receptor binding
A 2018 study in Current Medicinal Chemistry used radioligand-receptor methods and reported that Selank affected tritiated GABA binding in a manner the authors interpreted as positive allosteric modulation. The study also found that combined effects with selected benzodiazepines were not simply cumulative. This is biochemical mechanism evidence; it is not proof that a particular behavioural or clinical result will occur.
Gene expression in rat cortex and cultured cells
A 2016 rat frontal-cortex study measured 84 neurotransmission-related genes after exposure and reported time-dependent expression changes, including a positive correlation between early changes observed after Selank and GABA. A separate 2017 experiment in IMR-32 neuroblastoma cells found no changes in the measured genes with Selank alone, while combinations with GABA or olanzapine altered the expression pattern. Read together, these papers caution against reducing the proposed mechanism to one receptor or one universal transcriptional response.
Inhibitory synaptic currents
In rat hippocampal slices, a 2017 electrophysiology study reported increased amplitude and discharge rate of spontaneous inhibitory postsynaptic currents in CA1 pyramidal neurons. Some neurons showed a transient decrease before the increase, and the tested concentration range did not produce a clear dose dependence. The model offers a direct neural-physiology observation, but it remains an ex vivo rat-tissue result.
Possible opioid-system involvement
A 2012 mouse study used naloxone to probe whether opioid-system activity influenced behavioural responses to Selank. The results differed between mouse strains and led the authors to propose that the enkephalin-opioid system may contribute to individual variation. This is hypothesis-generating animal evidence, not a basis for predicting a human response.
What Does the Selank Evidence Base Actually Include?
| Evidence layer | Example observation | What it cannot establish alone |
|---|---|---|
| Receptor-binding assay | Changed radioligand GABA binding in isolated membrane preparations | Whole-organism behaviour, clinical benefit, or long-term safety |
| Cell culture | Context-dependent neurotransmission-gene expression in IMR-32 cells | Normal human brain response |
| Rat hippocampal slice | Changes in spontaneous inhibitory postsynaptic currents | Human psychological or clinical outcomes |
| Animal behaviour | Effects reported in stress, memory, withdrawal, and disease models | Direct translation across species or models |
| Human fMRI | Resting-state connectivity changes assessed in 52 healthy participants | Treatment efficacy or durable clinical outcomes |
| Small comparative clinical reports | Older studies reported symptom and tolerability measures | Large, independent, internationally replicated evidence |
Preclinical studies answer narrow questions
The preclinical literature is varied. For example, a 2022 rat study reported changes in signs measured in a naloxone-precipitated morphine-withdrawal model. Other indexed papers examine restraint stress, ethanol-related behaviour, memory models, cytokines, liver morphology, and intestinal tissue. These experiments show that Selank has been studied in multiple systems; their diversity is not a substitute for replication around one well-defined question.
What the human imaging study adds
A 2020 study evaluated resting-state functional connectivity before and after Selank, Semax, or placebo in 52 healthy participants. The investigators reported between-group and between-condition differences involving connectivity between the right amygdala and right temporal regions. Because the endpoint was short-term functional connectivity, it should not be rewritten as evidence of symptom relief, clinical effectiveness, or lasting neurological change.
What older human studies do—and do not—show
Two Russian-language PubMed records from 2014 and 2015 describe small comparative studies in anxiety-related diagnostic groups. One involved 60 participants comparing Selank with phenazepam; another compared phenazepam monotherapy in 30 participants with combined treatment in 40 participants. Their abstracts report favourable symptom or tolerability findings, but the records do not provide the detail needed here to independently assess allocation, masking, full statistical analysis, or generalizability. They are evidence that human research exists, not grounds for a clinical recommendation.
Selank vs Semax: What Is the Difference?
| Feature | Selank | Semax |
|---|---|---|
| Sequence lineage | Tuftsin-derived; Thr-Lys-Pro-Arg-Pro-Gly-Pro | ACTH(4–7)-derived analogue with Pro-Gly-Pro extension |
| Common research emphasis | GABAergic signalling, stress and anxiety models | Cognition, neuroprotection and neurotrophic signalling |
| Mechanistic themes | GABA binding, inhibitory currents, neurotransmission genes, possible opioid-system interaction | Neurotrophic and monoaminergic pathways discussed in its own literature |
| Human evidence | Limited imaging and small comparative reports | Separate, limited literature that must be evaluated on its own terms |
| Can results be transferred between them? | No. Similar research-community positioning does not make the compounds interchangeable. | |
For a separate evidence review, see BioPharma’s Semax peptide research guide. The Semax versus N-acetyl Semax comparison further illustrates why sequence variants require their own evidence analysis.
Research Limitations and Quality-Control Questions
Most evidence is preclinical
Cell, tissue, and animal studies are useful for mechanism development, but they do not establish a human-use protocol. Species, strain, model, endpoint, exposure conditions, and observation window can all change interpretation.
The human literature is small and concentrated
The accessible human record is limited compared with mature pharmaceutical evidence bases. Several reports come from a narrow set of institutions, some are available mainly through translated abstracts, and independent replication is sparse. Those limitations should appear beside any summary of positive findings.
Search quality affects evidence quality
The false-positive TP-7 results found during this article’s source audit are a practical warning: keyword counts are not evidence counts. A defensible review verifies title, abstract, model, endpoint, and citation identity. Readers building a broader foundation can start with BioPharma’s research peptides guide and 2026 research landscape.
Key Terms and Definitions
- Heptapeptide
- A peptide composed of seven amino-acid residues.
- Tuftsin
- The tetrapeptide Thr-Lys-Pro-Arg, which forms the first four residues of Selank.
- GABAergic signalling
- Cellular signalling involving gamma-aminobutyric acid, a major inhibitory neurotransmitter.
- Positive allosteric modulation
- Enhancement of receptor-related activity through a binding interaction distinct from the primary ligand site; the Selank paper inferred this from a specific binding assay.
- Resting-state functional connectivity
- A statistical relationship between spontaneous brain-imaging signals in different regions while a participant is not performing a task.
- Preclinical evidence
- Evidence from laboratory, cell, tissue, or animal work conducted before or outside confirmatory human trials.
Frequently Asked Questions About Selank Research
What is Selank?
Selank is the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. Published research describes it as a tuftsin analogue studied mainly in GABAergic, stress, behaviour, and neuropeptide models.
What does Selank research investigate?
The literature includes receptor-binding work, gene-expression and cell studies, rat hippocampal recordings, animal stress and behaviour models, and a small number of human studies. These evidence types answer different questions and should not be treated as interchangeable.
How might Selank interact with GABAergic signalling?
A 2018 molecular study reported effects on radioligand GABA binding consistent with positive allosteric modulation, while other studies observed changes in neurotransmission-related gene expression or inhibitory synaptic currents. These findings propose mechanisms; they do not prove a clinical outcome.
Is Selank a direct GABA-A receptor agonist?
The cited literature does not justify that simple label. It describes modulation of GABA-related binding, gene-expression, and synaptic measures, so “GABAergic modulator under investigation” is more precise.
What is the difference between Selank and Semax?
Selank is a tuftsin-derived sequence studied heavily in anxiety and stress models. Semax is an ACTH(4–7)-derived analogue with a different sequence and a literature base weighted more toward cognition and neuroprotection; neither should be inferred to work like the other.
Is there human research on Selank?
Yes, but it is limited. One 2020 resting-state fMRI study included 52 healthy participants, and older Russian-language comparative studies reported small clinical samples. These studies do not amount to a broad, independently replicated evidence base.
Is Selank related to tuftsin?
Yes. Selank is commonly described as a tuftsin analogue: it contains the tuftsin sequence Thr-Lys-Pro-Arg followed by Pro-Gly-Pro.
What does TP-7 mean in Selank discussions?
TP-7 is a shorthand used for the seven-amino-acid Selank sequence. Because TP-7 can have unrelated meanings in databases, literature searches should verify the title and abstract rather than relying on that keyword alone.
What are the main limitations of Selank research?
The evidence is geographically concentrated, much of it is preclinical, several human reports are small or available mainly through translated abstracts, and methods and endpoints vary substantially across studies.
Can this article be used for dosing or human-use guidance?
No. This is research education only. It provides no dosing, route, administration, treatment, efficacy, or safety instructions, and BioPharma materials are not intended for human or veterinary use.
Sources
- Volkova A, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Current Medicinal Chemistry. PMID 30255741.
- Medvedeva EV, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. PMID 26924987.
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. PMID 28293190.
- Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons. PMID 28361410.
- The role of the opioid system in the anti-anxiety effect of Selank. PMID 22550852.
- Functional Connectomic Approach to Studying Selank and Semax Effects. PMID 32342318.
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. PMID 36322304.
- A comparison of Selank and phenazepam in anxiety-disorder research. PMID 25176261.
- Optimization of anxiety-disorder treatment research with Selank. PMID 26356395.
- Tuftsin—Properties and Analogs. PMID 28745220.
Continue Exploring Research Peptides
Use the source list to evaluate Selank at the evidence level each study can support. Qualified researchers can also browse BioPharma’s Research Peptides category or review the compound research guide. Catalog listings are for research identification only and do not imply a dose, route, administration method, treatment, or expected outcome.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. BioPharma does not provide dosing, route, administration, treatment, efficacy, or safety guidance.
